Jefferies Reiterates Buy Rating on Xenon Pharmaceuticals (XENE): "We see a +50-75% stock move"
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $65.00 price target on Xenon Pharmaceuticals (NASDAQ: XENE)The analyst commented, "Azetukalner's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
